ARA-290
Also known as: Cibinetide
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Pricing for ARA-290
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$5.67/mg
range $2.50–$18.00/mg
Sellers
41
from $0.00
45-day trend
+1.8%
vs 45-day avg $/mg
33 of 41 sellers have a current price· 21 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 23h ago
$5.50/mg -2.9% vs avg$54.99
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · 22h ago
$6.33/mg +11.8% vs avg$95.00
15mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$6.50/mg +14.7% vs avg$65.00
10mg
- 🇺🇸 Peptide Plugs89
✓ verified at source · 23h ago
$5.00/mg -11.8% vs avg$50.00
10mg
99.8% purity 1 COA - 🇺🇸 Peptidology89
✓ verified at source · 23h ago
$5.50/mg -2.9% vs avg$54.99
10mg
99.8% purity 1 COA - 🇺🇸 Verified Peptides86
via Disclosed Labs · 23h ago
$5.42/mg -4.4% vs avg$65.00
12mg
98.4% purity 6 COAs - 🇺🇸 EZ Peptides85
✓ verified at source · 23h ago
$4.80/mg -15.3% vs avg$48.00
10mg
99.8% purity 2 COAs - 🇺🇸 Ascension Peptides84
via Disclosed Labs · 23h ago
$8.00/mg +41.2% vs avg$79.99
10mg
- 🇺🇸 OROS Research79
via Disclosed Labs · 23h ago
$3.75/mg -33.8% vs avg$120
32mg
99.0% purity 3 COAs - 🇺🇸 Certified Peptides62
✓ verified at source · 23h ago
$5.75/mg +1.5% vs avg$92.00
16mg
no purity 1 COA - peptidetech.isUnscored
via Disclosed Labs · 23h ago
$5.00/mg -11.8% vs avg$59.99
12mg
no purity - realpeptides.coUnscored
via Disclosed Labs · 23h ago
$5.31/mg -6.2% vs avg$85.00
16mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for ARA-290
50 third-party tests across 16 vendors. Each card links to the full report.
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Real Peptides· batch BATCH-0322
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
ARA-290
by OROS Research· batch OR-LPARA32-526-B1
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
ARA-290
by Riptide Wellness· batch RWARA-10-1002
For
ARA-290
by Verified Peptides· batch ARA04260312C
For
ARA-290
by Verified Peptides· batch ARA0426031 2C
For
ARA-290
by Glacier Aminos· batch ARA10GA-01
For
ARA-290
by Peptide Supply Co.· batch AR1022026
For
ARA-290
by BioLongevity Labs· batch 2-3-46035
For
ARA-290
by Ion Peptide· batch ARA10-01212026
For
ARA-290
by Ion Peptide· batch ARA10-01212026
For
ARA-290
by BioLongevity Labs· batch cmojb6w60016nkirxxcy5khmm
For
ARA290
by Mile High Compounds· batch ARA-012-MH-01
For
ARA-290
by Skye Peptides· batch ARA25-16-004
For
ARA-290
by Ion Peptide· batch ARA16-12082025
For
ARA290
by Orbitrex Peptides· batch ARA101225
For
ARA-290
by Ion Peptide· batch ARA16-12082025
16 citations indexed for ARA-290
animal · 2026
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.
review · 2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
A wound has been defined as a disruption of tissue integrity. Pain, bleeding, and the risk of infection are inherent features of wounds, while chronic wounds are often accompanied by serous exudate.
review · 2025
Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging
Cardiology is continually evolving towards increased personalization with targeted diagnostics and therapeutics.
animal · 2022
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression
Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.
animal · 2021
Synthesis and evaluation of <sup>99m</sup>Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region
Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.
animal · 2016
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.